

## IMPACT OF SMOKING ON COVID-19 PATIENTS: A CROSS-SECTIONAL STUDY

Mohammad Talha Khan<sup>\*1</sup>, Kaleem Ullah<sup>2</sup>

<sup>\*1,2</sup>Fauji Foundation Hospital – Warsak Road, Peshawar

<sup>1</sup>talhakhan95@yahoo.com, <sup>3</sup>mujtaba7khan@yahoo.com

### Keywords

Smoking, SARS-CoV2, COVID-19, ACE2, Nicotine

### Article History

Received: 01 January, 2025

Accepted: 21 February, 2025

Published: 31 March, 2025

### Copyright @Author

### Corresponding Author: \*

Mohammad Talha Khan

### Abstract

**Background:** COVID-19 primarily affects the respiratory system, with smokers showing varied behavioral responses during the pandemic. Some increased their smoking, while others reduced it. This study explores the underlying reasons behind these differing smoking habits during the COVID-19 crisis. **Methodology:** An online survey was conducted among 86 Pakistani university students (aged 18+), between March and May 2021, using Google Forms distributed via email and social media. **Results:** Among respondents, 98% were male, 65% held a bachelor's degree, and 55% were regular smokers. Of the participants, 53% had contracted COVID-19. Post-pandemic, 46% reported being non-smokers, 29% reduced smoking, 16% increased it, and 9% reported no change. **Conclusion:** Smoking may worsen COVID-19 outcomes by increasing respiratory vulnerability. The lung damage caused by smoking could heighten the severity of SARS-CoV2 infection, emphasizing the need for targeted smoking cessation efforts during respiratory pandemics.

## INTRODUCTION

Approximately 1.1 billion tobacco users worldwide are living in low-income countries where malnutrition poses a significant risk to immunity. Smokers also have a higher chance of developing a severe COVID-19 infection because of their weakened immune systems, susceptibility to cross-infection, and poor hygiene[1]. In individuals with COVID-19, male sex, older age, hypertension, diabetes, cardiovascular disease, and respiratory illness are risk factors for a bad prognosis [2]. As of July 28, 2020, 188 different countries had recorded 16,341,920 cases of severe acute respiratory syndrome coronavirus (SARS-CoV-2) infections, resulting in 650,805 fatalities. There is an urgent need for conclusive answers regarding the contentious impact of smoking on the clinical severity of COVID-19[3]. Due to damage to the upper respiratory tract and a reduction in pulmonary

immune function, smoking, and using e-cigarettes increase the risk and severity of respiratory infections[4]. Smokers, in particular, are more likely to contract COVID-19 and die from it[5]. The widespread chronic airway condition identified as chronic obstructive pulmonary disease (COPD) is characterized by an irreversible deterioration of lung functionality. COPD may be highly prevalent in the COVID-19 group and might worsen the clinical outcomes of these patients, as it makes sense given that COVID-19 primarily affects the respiratory system[6].

Acute respiratory distress syndrome (ARDS) can strike people with severe illness 8-12 days after the illness first manifests. Smoking has been linked to a higher chance of infection and poorer outcomes for numerous viral and bacterial infections[5,6]. In

addition, there is a range of 9.5 to 12 days from the start of the disease and admission to the intensive care unit (ICU). There are known risk factors for both severe COVID-19 and a higher chance of dying[9]. The link between tobacco use and the severity of COVID-19 infection is still contentious, despite consensus regarding the correlation between severe COVID-19 and the comorbidities listed above[7]. Smokers have a five-fold increased risk of influenza and a two-fold increased risk of pneumonia. Tobacco smoking is a significant risk factor for both bacterial and viral respiratory infections[10]. Under such conditions, it is crucial to investigate the connections between smoking and Covid-19 in more detail and ascertain whether these connections are due to the effects of nicotine or smoke itself [11].

Fever and respiratory symptoms, including cough, sputum production, and dyspnea, are the primary clinical symptoms. Extrapulmonary symptoms such as diarrhea, liver and renal damage, and heart function impairment can appear in certain people. Acute respiratory distress syndrome, multiple organ dysfunction syndromes, and even death are possible presentations for some patients with severe illness[12]. Smoking has been linked to an increased risk of acquiring many respiratory viral diseases, such as MERS, RSV, influenza, and others. Smoking causes inflammation of the lung epithelium, which damages the epithelial cells and results in the production of cytokines, increased mucus secretion, and poor mucociliary clearance[13]. Nicotine chemical compounds cause blood clotting and deadly embolism by damaging blood vessels, dissolving the lungs' protective lining, and altering the endothelium's surface[14].

Furthermore, the mortality rate for COVID-19 infections in smokers are 25.8%. Therefore, it is challenging to enforce stringent cross-infection controls when smoking is present. Smoking increases the risk of COVID-19 spreading from hand to mouth since it involves putting fingers and tainted cigarette shafts in contact with lips[15]. Even when people take precautions to keep a safe distance from smokers, contaminated surfaces, the air around them, and aerosol from smoking tobacco through different devices can passively infect non-smokers[16]. In a sample of patients with lung adenocarcinoma, it was recently discovered that, after adjusting for age,

gender, and ethnicity, ACE2 gene expression is higher in ever smokers (both present and past) compared with never smokers in normal lung tissue[17]. Tobacco usage and the risk of COVID-19 infection are not entirely related, according to the epidemiological data. However, there is convincing evidence linking tobacco use to worse clinical outcomes, such as an increased risk of mortality; smokers who are currently using tobacco have a higher probability of dying in hospitals (9.4% vs. 5.6% for nonsmokers)[18].

Smoking has not been linked to the severity of COVID-19, even though previous research has examined several risk variables, but they have still lack of association between smoking and Covid-19 which will be defined in this study. This study have an important view on the severity of Covid symptoms and smoking as well. However this study investigates the connection between an individual's smoking behavior and the severity of their COVID-19 infection. The research highlights the elevated risk that smokers experience, establishing a link between smoking and a higher vulnerability to serious problems. The results demonstrate the complex interactions between respiratory disorders caused by smoking and the worsening of COVID-19 symptoms. The significance of focused public health initiatives is underscored by these findings, particularly as the world community struggles to contain the pandemic. Reducing smoking and encouraging quitting are essential for respiratory health in general as well as for minimizing the impact of COVID-19 on people that are vulnerable around the world. Even though the study provides insightful information, further research is necessary to fully understand every aspect of this relationship and develop more advanced public health solutions that will protect people and communities all around the world.

## Aims and Objectives

1. To investigate whether smoking status and the severity of COVID-19 symptoms in patients are correlated.
2. To examine how the disease progresses in smokers and non-smokers.
3. To evaluate the relationship between smoking and comorbidities, or preexisting medical conditions that could potentially make COVID-19 outcomes more severe.

## Methodology:

### Study Design:

The current study aimed to identify the effect of smoking on covid-19 patients and its severity. For this reason a descriptive cross-sectional online survey study was conducted, in order to explore symptoms severity of covid-19 patients in relation to smoking. The past smokers are also consider current smokers in the study.

### Study Setting and Period:

This study was conducted in different college/university students of Pakistan by sending online Google forms to their email/whatsapp. A cross-sectional study was carried from March 2021 to May 2021 after permission from ethical review board. One month was spent for data collection, one month for data analyses and one month for report writing.

### Sample size:

The sample size was calculated through Expanded Program on Immunization (EPI) portal of Centers for Disease Control and Prevention (CDC). By calculation the researcher obtained 86 sample size with reference population of 8000 multiple college/university students studying in Pakistan with 95% confidence level, 5% margin of error and response distribution is 50%.

### Sampling Technique and Selection:

A self-designed questionnaire with two parts was used: the first part included consent, demographics, level of education, and any comorbidities, and the second part included questions about their smoking status, SARS CoV-2, family/friends smoking status and their covid-19 history and symptoms severity during the COVID-19 infection.

**Table 1 Demographics**

Demographics			
Variable		Frequency	Percentage
Gender	Female	2	2
	Male	84	98
Education level	12 years	22	26
	Bachelor	56	65
	< Matric	2	2
	Master	6	7

### Inclusion Criteria:

Inclusion criteria were as follows:

- COVID-19 patients older than 18 years and diagnosed COVID-19 according to WHO criteria
- Current smokers with mild and severe COVID-19

### Exclusion Criteria:

Exclusion criteria were as follows:

- COVID-19 patients less than 18 years
- Non-smokers

### Data Collection Procedure:

A semi structured questionnaire created on Google forms was circulated and was filled by college/university students. Data was obtained in form of excel sheet.

### Data Analysis:

Data analysis was done by using Microsoft excel software and SPSS version 20.0 by IBM Corporation. Frequencies, percentages, means and standard deviations will be calculated and in order to compare means across gender independent sample “T test” will also be calculated.

### Expected Outcomes:

Relation between smoking and covid-19 and its progression of symptoms.

### Results

Gender distribution shows 98% were male, 2% of them were females. 65% participants were Bachelor. 95% of Participants didn't have any chronic disease, 55% were regular smokers, 53% had acquired COVID19 infection once as shown in table 1.

Chronic Disease	No	82	95
	Yes	4	5
Past Smoker/Smoker	No	38	44
	Yes	48	55.8
COVID Virus Infection	No	40	46.5
	Yes	46	53.5
Smokers in Family	No	18	20.9
	Yes	68	79.1
COVID Infection in family members	No	36	41.9
	Yes	50	58.1

As shown in figure 1, most of participants were holding bachelor's degree.





Figure 1 Table of demographics

Table 2 Descriptive

		Smoking	Frequency	Percentage
After COVID Pandemic	Non smoker		40	46.51163
	I smoke less than usual		24	27.90698
	Smoke more		14	16.27907
	Smoke as usual		8	9.3023256

When participants were asked if they had any change in their smoking habit after COVID19 pandemic, 46% were non-smokers, why half of rest 54% tended to smoke less after covid19 pandemic. 16 percent

stated they are smoking more than usual while 9% were smoking as they were before pandemic as shown in table 2.



**Figure 2 Smoking routine after covid19 routine**  
**Figure 2 shows smoking routine among participant after pandemic.**

In table 4, age and mean of age and symptom severity, mean of symptom severity of (N= 86) participants was 3.61, while mean for age was 25.72.

**Table 3 Descriptive Statistics**

Descriptive Statistics					
Parameters	N	Minimum	Maximum	Mean	Std. Deviation
COVID-19					
Symptom severity	86	0	9	3.6162791	3.087617
on Scale 1-10					
Age	86	18	46	25.72093	5.7284659

T-test was run on symptom severity between smokers and non-smokers. Results showed (N=86), mean of symptom severity, Smoker ( $M=4.00$ ,  $S.D=2.975$ ), while for non-smokers ( $M=3.13$ , and  $S.D=3.19$ ) with  $t=1.30$  and  $p=0.1$  as shown in table 5.

**Table 4 Hypothesis Testing (Independent t-test)**

Groups	Smoker		Non Smoker		t	p	95%CL	
	n=48	M	n=38	S.D			LL	UL
Symptom Severity	4.00	2.975	3.131	3.19	1.30	0.106	-0.472	2.20

**Discussion:**

Previous research on smoking cessation has emphasized the need to examine the patient's smoking status, sensitizing them about smoking, and

encouraging them to quit[19]. However the likelihood of contracting a tobacco-associated COVID-19 infection can be minimized after reducing smoking is an important topic to answer in order to establish

causality as well as to advise and effectively treat patients[20]. The results of the meta-analysis indicate a correlation between the severity of SARS-CoV-2 and concomitant conditions such diabetes, COPD, and previous cardiovascular illness in some studies[21]. In relation to smoking and COVID-19, our data revealed a pooled prevalence of 16% current smokers (95% CI, 4%–14%), which is less than the 25.2% (25.1–25.4) estimated smoking prevalence in China[22].

The quality of data in China, the US, and other countries is unknown given the pandemic's conditions. However, hospitalized COVID-19 patients also had a similarly low smoking prevalence, even if a superior data collection technique had been employed to report smoking conditions[23]. The most recent systematic review summarized the key data to date and focused on the role of smoking in COVID-19 severity and mortality. It was released in pre-print on May 23, 2020. It looked at 22 studies that reported hospitalized patients' illness severity based on their smoking status[24]. Consistent with recent findings, the clinical features of 2019-nCoV ARD resembled those of SARS-CoV. In contrast to SARS-CoV, MERS-CoV, and influenza, fever and cough were the most common symptoms, whereas gastrointestinal symptoms were uncommon. This suggests that the viral tropism is different[25].

Furthermore; the increase of ACE2 expression in the respiratory tract is caused by cigarette smoke. But experts also understand that certain parts of cigarettes, such as nicotine, may affect ACE2 differently from entire smoke, and that smoking itself may change the amount of ACE2 in non-respiratory organs in distinct ways[26]. However, the evaluation of smoking history's impact on disease progression showed a considerable degree of variability, which is probably due to significant inter-study differences in how progression is defined [27].

By using a standardized questionnaire and precise criteria for smoking history and illness stages, our smoking-focused study demonstrates a significant and favorable effect size of smoking history for disease severity. Other epidemiology papers on the impacts of smoking may have inconsistent study designs with various findings[28], such as focusing exclusively on "current" smokers, patients who have not yet had a hospitalization outcome, or not having a criterion for smoking history or "survivors," as has been

acknowledged. In this regard, by referencing relevant research and examining the connections between smoking, exercise, and the severity of COVID-19, our findings add to the growing body of literature[29]. Five previous research results indicate that patients with and without a history of smoking do not significantly differ in terms of COVID-19 severity. The results of the previously published investigations are in conflict with this study[30].

### Conclusion

In conclusion, the thorough investigation of the association between smoking and COVID-19 cases highlights how crucial it is to recognize the possible effects of tobacco use on respiratory health in the event of a worldwide pandemic. While the data currently available indicates that smokers may be more vulnerable to serious consequences from viral infection, more investigation is required. Initiatives in the field of public health should keep stressing the harmful consequences of smoking on an individual's general health, paying special emphasis on how smoking could increase the severity of COVID-19. The results highlight the need for comprehensive tobacco control policies and initiatives to help people quit smoking to reduce risks and safeguard vulnerable groups against the combined threats of smoking and COVID-19. Ultimately, addressing the complex interactions between smoking and COVID-19 outcomes and fostering a stronger and more resilient global community requires a multimodal strategy which includes rigorous research, public awareness campaigns, and focused treatments.

### Future Prospects

The current COVID-19 epidemic should be investigated in relation to tobacco use in both the nicotine and tobacco research communities. To support the link between smoking and COVID-19, additional evidence is required. It is important to locate databases and conduct analyses that concentrate on the relationship between this correlation and viral infection, sickness severity, recovery potential, and other factors. Data on smoking status among COVID-19 patients should be systematically collected and examined. For smokers with COVID-19 symptoms, we require information regarding the short- and immediate-term benefits of

prevention. Quantifying the quantity of infectious agents present in tobacco products should be a primary objective of laboratory research, with shared items like water pipes receiving special attention. Information regarding the risk/benefit ratio for different nicotine delivery methods with COVID-19 will also be required.

### Conflict of Research

There is no conflict of research.

### REFERENCES

- [1] “The Effect of Smoking on COVID-19 Symptom Severity: Systematic Review and Meta-Analysis.”
- [2] P. Godoy, J. Castilla, ... N. S.-... E. J. of, and U. 2018, “Smoking may increase the risk of influenza hospitalization and reduce influenza vaccine effectiveness in the elderly,” vol. 28, no. 1, pp. 150–155, 2018.
- [3] A. Gülsen, B. A. Yigitbas, B. Uslu, D. Drömann, and O. Kilinc, “The Effect of Smoking on COVID-19 Symptom Severity: Systematic Review and Meta-Analysis,” Pulmonary Medicine, vol. 2020, 2020, doi: 10.1155/2020/7590207.
- [4] G. Lippi and B. M. Henry, “Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19),” European Journal of Internal Medicine, vol. 75, pp. 107–108, May 2020, doi: 10.1016/J.EJIM.2020.03.014.
- [5] R. Patanavanich, S. G.-N. and tobacco Research, and U. 2020, “Smoking is associated with COVID-19 progression: a meta-analysis,” academic.oup.com, vol. 22, no. 9, pp. 1653–1656, 2020, Accessed: Jan. 06, 2024. [Online]. Available: <https://academic.oup.com/ntr/article-abstract/22/9/1653/5835834>
- [6] D. Lacedonia, G. Scioscia, C. Santomas, P. F.-S. Reports, and U. 2021, “Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients,” nature.com, vol. 11, 2021, Accessed: Jan. 06, 2024. [Online]. Available: <https://www.nature.com/articles/s41598-021-98749-4>
- [7] D. Puebla Neira, A. Watts, J. Seashore, E. Polychronopoulou, Y. F. Kuo, and G. Sharma, “Smoking and risk of COVID-19 hospitalization,” Respiratory Medicine, vol. 182, p. 106414, Jun. 2021, doi: 10.1016/J.RMED.2021.106414.
- [8] Y. Cao, X. Liu, L. Xiong, K. C.-J. of medical Virology, and U. 2020, “Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis,” Wiley Online LibraryY Cao, X Liu, L Xiong, K CaiJournal of medical virology, 2020 • Wiley Online Library, vol. 92, no. 9, pp. 1449–1459, 2020, Accessed: Dec. 30, 2023. [Online]. Available: [https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25822?casa\\_token=4iOVTTnlZJcAAAAA:S91\\_MbiPhsHDZAKZpmg\\_WL1XKsYxelGw5WNB3JM7GWpxKg7cD0COk4FG9YpXj-Is6AzHMuoYvRyc5XQ](https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25822?casa_token=4iOVTTnlZJcAAAAA:S91_MbiPhsHDZAKZpmg_WL1XKsYxelGw5WNB3JM7GWpxKg7cD0COk4FG9YpXj-Is6AzHMuoYvRyc5XQ)
- [9] P. Godoy et al., “Smoking may increase the risk of influenza hospitalization and reduce influenza vaccine effectiveness in the elderly,” European Journal of Public Health, vol. 28, no. 1, pp. 150–155, Feb. 2018, doi: 10.1093/EURPUB/CKX130.
- [10] N. Hopkinson, N. Rossi, J. E.-S.- Thorax, and undefined 2021, “Current smoking and COVID-19 risk: results from a population symptom app in over 2.4 million people,” thorax.bmj.com, Accessed: Jan. 06, 2024. [Online]. Available: <https://thorax.bmj.com/content/thoraxjnl/early/2021/02/07/thoraxjnl-2020-216422.full.pdf>
- [11] N. Paleiron et al., “Impact of Tobacco Smoking on the Risk of COVID-19: A Large Scale Retrospective Cohort Study,” Nicotine & Tobacco Research, vol. 23, no. 8, pp. 1398–1404, Aug. 2021, doi: 10.1093/NTR/NTAB004.

[12] Y. He et al., "Association between smoking and COVID-19 severity: A multicentre retrospective observational study," [ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov), Accessed: Jan. 06, 2024. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302364/>

[13] M. Adrish, S. Chilimuri, N. Mantri, ... H. S.-B. open respiratory, and undefined 2020, "Association of smoking status with outcomes in hospitalised patients with COVID-19," [ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov), Accessed: Jan. 06, 2024. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536635/>

[14] J. González-Rubio et al., "A systematic review and meta-analysis of hospitalised current smokers and COVID-19," vol. 17, no. 20, p. 7394, 2019, doi: 10.3390/ijerph17207394.

[15] W. Guan et al., "Clinical Characteristics of Coronavirus Disease 2019 in China," *New England Journal of Medicine*, vol. 382, no. 18, pp. 1708–1720, Apr. 2020, doi: 10.1056/NEJMoa2002032.

[16] F. R. Guo, "Smoking links to the severity of COVID-19: An update of a meta-analysis," *Journal of Medical Virology*, vol. 92, no. 11, pp. 2304–2305, Nov. 2020, doi: 10.1002/JMV.25967.

[17] I. Berlin, D. Thomas, ... A. L. F.-N. and T., and undefined 2020, "COVID-19 and smoking," [academic.oup.com](https://academic.oup.com), Accessed: Jan. 06, 2024. [Online]. Available: <https://academic.oup.com/ntr/article-abstract/22/9/1650/5815378>

[18] M. Çörtük Sağlık Bilimleri Üniversitesi et al., "Is there any effect of smoking status on severity and mortality of hospitalized patients with COVID-19 pneumonia," [researchgate.net](https://www.researchgate.net), vol. 68, no. 4, pp. 371–378, 2020, doi: 10.5578/tt.70352.

[19] B. Kayhan Tetik, I. Gedik Tekinemre, and S. Taş, "The Effect of the COVID-19 Pandemic on Smoking Cessation Success," *Journal of Community Health*, vol. 46, no. 3, pp. 471–475, Jun. 2021, doi: 10.1007/S10900-020-00880-2.

[20] V. K. Kashyap et al., "Smoking and COVID-19: adding fuel to the flame," [mdpi.com](https://www.mdpi.com), doi: 10.3390/ijms21186581.

[21] F. Del Sole, A. Farcomeni, ... L. L.-E. journal of, and undefined 2020, "Features of severe COVID-19: a systematic review and meta-analysis," *Wiley Online Library*F Del Sole, A Farcomeni, L Loffredo, R Carnevale, D Menichelli, T Vicario, P PignatelliEuropean journal of clinical investigation, 2020•Wiley Online Library, vol. 50, no. 10, Oct. 2020, doi: 10.1111/eci.13378.

[22] J. S. Alqahtani, T. Oyelade, A. M. Aldhahir, and S. M. Alghamdi, "Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: A rapid systematic review and meta-analysis," *PLoS ONE*, vol. 15, no. 5, May 2020, doi: 10.1371/JOURNAL.PONE.0233147.

[23] Y. He et al., "Association between smoking and COVID-19 severity: A multicentre retrospective observational study," [ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov), Accessed: Jan. 07, 2024. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302364/>

[24] S. Gallus, A. Lugo, G. G.-E. journal of internal medicine, and undefined 2020, "No double-edged sword and no doubt about the relation between smoking and COVID-19 severity," [ejinme.com](https://www.ejinme.com), Accessed: Jan. 08, 2024. [Online]. Available: [https://www.ejinme.com/article/S0953-6205\(20\)30252-1/abstract](https://www.ejinme.com/article/S0953-6205(20)30252-1/abstract)

[25] W. Guan et al., "Clinical characteristics of 2019 novel coronavirus infection in China," [medrxiv.org](https://www.medrxiv.org), Accessed: Dec. 30, 2023. [Online]. Available: <https://www.medrxiv.org/content/10.1101/2020.02.06.20020974V1.full>

[26] J. Smith, E. Sausville, V. Girish, M. Y.-D. cell, and undefined 2020, "Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract," cell.com, Accessed: Dec. 30, 2023. [Online]. Available: [https://www.cell.com/developmental-cell/pdf/S1534-5807\(20\)30401-9.pdf](https://www.cell.com/developmental-cell/pdf/S1534-5807(20)30401-9.pdf)

[27] R. K. Reddy, W. N. Charles, A. Sklavounos, A. Dutt, P. T. Seed, and A. Khajuria, "The effect of smoking on COVID-19 severity: A systematic review and meta-analysis," Journal of Medical Virology, vol. 93, no. 2, pp. 1045–1056, Feb. 2021, doi: 10.1002/JMV.26389.

[28] A. Gülsen, B. Yigitbas, B. Uslu, ... D. D.-P., and undefined 2020, "The effect of smoking on COVID-19 symptom severity: systematic review and meta-analysis," hindawi.com, Accessed: Jan. 08, 2024. [Online]. Available: <https://www.hindawi.com/journals/pm/2020/7590207/>

[29] M. UCA, ... K. S.-P. J. of M., and undefined 2021, "Investigating the Impacts of Smoking and Exercise History on the Recovery Course among Covid-19 Patients," pjmhsonline.com, vol. 15, no. 10, 2021, doi: 10.53350/pjmhs2115102977.

[30] M. Mustafa Assem , D. Falih Ahmed , and M. Badr Mahmood, "Association of smoking type, status, number times of smoking and their effect on infected people by COVID-19," Diyala Journal of Medicine, vol. 23, no. 1, pp. 88–98, 2022, doi: 10.26505/djm.v23i1.929.